Dendrogenix reports the publication of new preclinical results highlighting the ability of DX243 to protect the most vulnerable auditory circuits from age-related degeneration.
Published in Frontiers in Pharmacology (2026), this study from the Tübingen Hearing Research Centre (University of Tübingen, Germany) demonstrates that a 14-day daily treatment with DX243 preserves the functional integrity of critical auditory synapses involved in temporal sound processing and speech understanding in noisy environments—capabilities that decline early in Age-Related Hearing Loss (presbycusis).
Protective effects persist for up to 6 weeks after treatment cessation, supporting a durable disease-modifying effect on cochlear synaptopathy rather than short-term symptomatic relief.
Unlike ...